Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT05613088 · Bristol-Myers Squibb · PHASE2 · terminated · last registry update 2026-10-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business objectives have changed.” | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-09Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLS5132 + Liposomal Doxorubicin (NCT07926048)
- 2026-11-05Phase 3 first posted: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Chemotherapy (NCT07920549)
- 2026-11-04Also stopped (terminated): City of Hope Medical Center, carboplatin + dasatinib (NCT00788125)
- 2026-11-02Phase 3 first posted: AstraZeneca, Surovatamig + Rituximab (NCT07911553)
- 2026-10-29Results posted on the registry: City of Hope Medical Center, Bleomycin + Brentuximab Vedotin (NCT03712202)
- 2026-10-27Also stopped (suspended): National Cancer Institute (NCI), Cabozantinib S-malate + Cisplatin (NCT05691478)
- 2026-10-22Also stopped (withdrawn): City of Hope Medical Center, Bortezomib + Daratumumab (NCT03591744)
- 2026-10-22Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Carboplatin (NCT03036488)
- 2026-10-21Results posted on the registry: Incyte Biosciences Japan GK, tafasitamab + lenalidomide (NCT04661007)
- 2026-10-21Also stopped (terminated): Medical College of Wisconsin, Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen + Cladribine and Cytarabine (CLLDAC) Regimen (NCT03150004)
- 2026-10-19Phase 3 first posted: Jiangsu Simcere Pharmaceutical Co., Ltd., Trilaciclib + Etoposide Injection (NCT07881705)
- 2026-10-19Results posted on the registry: InSightec, a drug against TOP2A (NCT02343991)
- 2026-10-19Also stopped (terminated): Novartis Pharmaceuticals, Alpelisib + Olaparib (NCT04729387)
- 2026-10-15Results posted on the registry: St. Jude Children's Research Hospital, CPX-351 + MHA (NCT05656248)
- 2026-10-06Results posted on the registry: National Cancer Institute (NCI), Cytarabine + Daunorubicin (NCT04817241)
- 2026-10-06Also stopped (terminated): Alaunos Therapeutics, Palifosfamide-Tris + doxorubicin (NCT01168791)
- 2026-10-05Also stopped (terminated): Alaunos Therapeutics, Palifosfamide-Tris + Doxorubicin (NCT00718484)
- 2026-10-05Also stopped (terminated): Children's Oncology Group, Cyclophosphamide + Doxorubicin Hydrochloride (NCT06820957)
- 2026-10-01Phase 3 first posted: Tanta University, Doxorubicin + Empaglifloz 5 mg orally once daily (NCT07852546)
- 2026-10-01Also stopped (terminated): Alaunos Therapeutics, Carboplatin + Palifosfamide-tris (NCT01555710)
- 2026-09-30Phase 3 first posted: The Affiliated People's Hospital of Ningbo University, rhTPO prophylaxis plus EAP stem-cell mobilization (NCT07848672)
- 2026-09-29Also stopped (suspended): University of Washington, Asparaginase Erwinia chrysanthemi + Cyclophosphamide (NCT06738368)
- 2026-09-23Also stopped (withdrawn): M.D. Anderson Cancer Center, Revumenib + Cytrabine (NCT07052994)
- 2026-09-22Phase 3 first posted: Suzhou Zelgen Biopharmaceuticals Co.,Ltd, ZG005 for Injection + Etoposide Injection (NCT07833839)
- 2026-09-18Also stopped (terminated): Pusan National University Yangsan Hospital, dose dense MVAC with pegylated GCSF (NCT04047693)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision